Exosome-derived microrna biomarker isolated from duodenal pancreatic juice for diagnosis of pancreatic cancer and uses thereof

WO2026127238A1PCT designated stage Publication Date: 2026-06-18THE ASAN FOUND +2
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
THE ASAN FOUND
Filing Date
2025-06-13
Publication Date
2026-06-18

AI Technical Summary

⚠Technical Problem

Current diagnostic methods for pancreatic cancer are inadequate, particularly in early stages, leading to low treatment efficacy and poor prognosis due to late detection, and existing biomarkers in blood and urine lack specificity for pancreatic cancer.

⚗Method used

Utilization of exosome-derived microRNAs (miRNAs) isolated from duodenal pancreatic fluid, specifically miR-320b, miR-423-5p, miR-155-5p, miR-101-3p, miR-148a-3p, miR-320a-3p, miR-1298-5p, miR-200a-5p, miR-30e-3p, miR-191-5p, Let-7a-5p, and Let-7f-5p, for diagnosing pancreatic cancer through non-invasive means by measuring their expression levels.

🎯Benefits of technology

The exosome-derived miRNAs exhibit high diagnostic specificity and sensitivity for pancreatic cancer, enabling early detection and predicting disease progression and treatment response.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2025008175_18062026_PF_FP_ABST
    Figure KR2025008175_18062026_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to an exosome-derived miRNA biomarker isolated from duodenal pancreatic juice for the diagnosis of pancreatic cancer and uses thereof. More specifically, the present invention includes a miRNA biomarker capable of diagnosing pancreatic cancer, a composition for diagnosing pancreatic cancer using same, and a method for providing diagnostic information for pancreatic cancer using same. The miRNA presented in the present invention exhibits excellent diagnostic specificity and sensitivity for pancreatic cancer, and thus can be advantageously used not only for early diagnosis of pancreatic cancer through a non-invasive method, but also for predicting the progression of and therapeutic response for pancreatic cancer.
Need to check novelty before this filing date? Find Prior Art